139 related articles for article (PubMed ID: 16946301)
1. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4.
Kawai T; Choi U; Cardwell L; DeRavin SS; Naumann N; Whiting-Theobald NL; Linton GF; Moon J; Murphy PM; Malech HL
Blood; 2007 Jan; 109(1):78-84. PubMed ID: 16946301
[TBL] [Abstract][Full Text] [Related]
2. Genetics on a WHIM.
Al Ustwani O; Kurzrock R; Wetzler M
Br J Haematol; 2014 Jan; 164(1):15-23. PubMed ID: 24111611
[TBL] [Abstract][Full Text] [Related]
3. Periodontal disease in patients with WHIM syndrome.
Brenchley L; McDermott DH; Gardner PJ; Silva LM; Gao JL; Cho E; Velez D; Moutsopoulos NM; Murphy PM; Fraser D
J Clin Periodontol; 2024 Apr; 51(4):464-473. PubMed ID: 38185798
[TBL] [Abstract][Full Text] [Related]
4. CXCR4: from B-cell development to B cell-mediated diseases.
Giorgiutti S; Rottura J; Korganow AS; Gies V
Life Sci Alliance; 2024 Jun; 7(6):. PubMed ID: 38519141
[TBL] [Abstract][Full Text] [Related]
5. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
Dale DC; Firkin F; Bolyard AA; Kelley M; Makaryan V; Gorelick KJ; Ebrahim T; Garg V; Tang W; Jiang H; Skerlj R; Beaussant Cohen S
Blood; 2020 Dec; 136(26):2994-3003. PubMed ID: 32870250
[TBL] [Abstract][Full Text] [Related]
6. Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the acute myeloid leukemia burden.
Biondi M; Tettamanti S; Galimberti S; Cerina B; Tomasoni C; Piazza R; Donsante S; Bido S; Perriello VM; Broccoli V; Doni A; Dazzi F; Mantovani A; Dotti G; Biondi A; Pievani A; Serafini M
Blood; 2023 May; 141(21):2587-2598. PubMed ID: 36787509
[TBL] [Abstract][Full Text] [Related]
7. Pluronic-F127/Platelet Microvesicles nanocomplex delivers stem cells in high doses to the bone marrow and confers post-irradiation survival.
Chander V; Gangenahalli G
Sci Rep; 2020 Jan; 10(1):156. PubMed ID: 31932650
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 WHIM syndrome is a cancer predisposition condition for virus-induced malignancies.
Moulin C; Beaupain B; Suarez F; Bertrand Y; Beaussant SC; Fischer A; Durin J; Ranta D; Espéli M; Bachelerie F; Bellanné-Chantelot C; Molina T; Emile JF; Balabanian K; Deback C; Donadieu J
Br J Haematol; 2024 Apr; 204(4):1383-1392. PubMed ID: 38442908
[TBL] [Abstract][Full Text] [Related]
9. CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance.
Pitt LA; Tikhonova AN; Hu H; Trimarchi T; King B; Gong Y; Sanchez-Martin M; Tsirigos A; Littman DR; Ferrando AA; Morrison SJ; Fooksman DR; Aifantis I; Schwab SR
Cancer Cell; 2015 Jun; 27(6):755-68. PubMed ID: 26058075
[TBL] [Abstract][Full Text] [Related]
10. Gene silencing on a WHIM.
Gennery AR
Blood; 2023 Jul; 142(1):1-2. PubMed ID: 37410507
[No Abstract] [Full Text] [Related]
11. Phase 3 randomized trial of mavorixafor, CXCR4 antagonist, in WHIM syndrome.
Badolato R; Alsina L; Azar A; Bertrand Y; Bolyard AA; Dale DC; Deyà-Martinez À; Dickerson KE; Ezra N; Hasle H; Kang HJ; Kiani-Alikhan S; Kuijpers TW; Kulagin A; Langguth D; Levin C; Neth O; Olbrich P; Peake J; Rodina Y; Rutten CE; Shcherbina A; Tarrant TK; Vossen MG; Wysocki CA; Belschner A; Bridger GJ; Chen K; Dubuc S; Hu Y; Jiang H; Li S; MacLeod R; Stewart M; Taveras AG; Yan T; Donadieu J
Blood; 2024 Apr; ():. PubMed ID: 38643510
[TBL] [Abstract][Full Text] [Related]
12. Dale DC, Firkin F, Bolyard AA, et al. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome. Blood. 2020;136(26):2994-3003.
Blood; 2023 Jun; 141(26):3232. PubMed ID: 37383001
[No Abstract] [Full Text] [Related]
13. CXCR4 chemokine antagonist scores a first FDA approval for WHIM syndrome.
Mullard A
Nat Rev Drug Discov; 2024 May; ():. PubMed ID: 38740965
[No Abstract] [Full Text] [Related]
14. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.
Dotta L; Tassone L; Badolato R
Curr Mol Med; 2011 Jun; 11(4):317-25. PubMed ID: 21506920
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9-mediated Cxcr4 disease allele inactivation for gene therapy in a mouse model of WHIM syndrome.
Gao JL; Owusu-Ansah A; Yang A; Yim E; McDermott DH; Jacobs P; Majumdar S; Choi U; Sweeney CL; Malech HL; Murphy PM
Blood; 2023 Jul; 142(1):23-32. PubMed ID: 36928087
[TBL] [Abstract][Full Text] [Related]
16. Reduced G protein signaling despite impaired internalization and β-arrestin recruitment in patients carrying a CXCR4Leu317fsX3 mutation causing WHIM syndrome.
Kumar R; Milanesi S; Szpakowska M; Dotta L; Di Silvestre D; Trotta AM; Bello AM; Giacomelli M; Benedito M; Azevedo J; Pereira A; Cortesao E; Vacchini A; Castagna A; Pinelli M; Moratto D; Bonecchi R; Locati M; Scala S; Chevigné A; Borroni EM; Badolato R
JCI Insight; 2023 Mar; 8(5):. PubMed ID: 36883568
[TBL] [Abstract][Full Text] [Related]
17. Dynamin-2 deficiency causes age- and sex-dependent neutropenia and myelodysplasia in mice.
Willis AJ; Corey SJ; Murga-Zamalloa C; Karimi SS; Khaddour K; Quigley J; Eklund EA; Chen Y
Blood Adv; 2023 Apr; 7(8):1418-1431. PubMed ID: 36417761
[TBL] [Abstract][Full Text] [Related]
18. Targeting CXCR4 and CD47 Receptors: An Overview of New and Old Molecules for a Biological Personalized Anticancer Therapy.
Leo M; Sabatino L
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293358
[TBL] [Abstract][Full Text] [Related]
19. Altered CXCR4 dynamics at the cell membrane impairs directed cell migration in WHIM syndrome patients.
García-Cuesta EM; Rodríguez-Frade JM; Gardeta SR; D'Agostino G; Martínez P; Soler Palacios B; Cascio G; Wolf T; Mateos N; Ayala-Bueno R; Santiago CA; Lucas P; Llorente L; Allende LM; González-Granado LI; Martín-Cófreces N; Roda-Navarro P; Sallusto F; Sánchez-Madrid F; García-Parajo MF; Martínez-Muñoz L; Mellado M
Proc Natl Acad Sci U S A; 2022 May; 119(21):e2119483119. PubMed ID: 35588454
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
